Oncolytics Biotech Inc T.ONC

Checkpoint drugs' regulatory reckoning looms

[askretka]

This could be very good news for Oncolytics because remember Pela enhances Checkpoint inhibitors and with the latest CAR T data a second boost helped even more. They will be looking at the data and may be able to use the Checkpoint inhibitors plus Pela for cancers thay The FDA had under review. Interesting it coming in April as well but I don't know the date. April could be a very pivotal month for Oncolytics. Cheers! ----------------------------------- Checkpoint drugs'regulatory reckoninglooms The FDA is turning the trickle of immunotherapy accelerated approval withdrawals in the US the latest beingRochesMondayannouncementthat it will pull PD-L1 drug Tecentriq from bladder cancer three years after it failed a confirmatory trial into a little pond. In an unprecedented three-day advisory committeemeetingscheduled for April, the agency will ask outside experts to weigh in on whether six other snap OKs forTecentriq,Mercks KeytrudaandBristol Myers Squibbs Opdivoshould be revoked, too.Richard Pazdursteam at the Oncology Center of Excellence, though, will have the final say, Zach Brennan reports.

[HCallahann44]

thx for posting....but how is this good news??? don't we need those CIs on the market?

[Capitalista]

Hi.  Newbie poster here, but I've been long on ONC for years and a longtime lurker on these boards.  Cancellation of approval for those CIs could be a mixed blessing, I'm thinking.  On the one hand, the biggies may just drop those compounds from their lineup.  That's a cost-benefit calculation they have to do themselves.   On the other hand (and more

[askretka]

It's only for certain types of cancers. Opdvio for instance is being used or tried for 14 cancer types at the moment. I had same thoughts as you when I saw the article. More research and reading and if one of the drugs can't be used for one type of cancer if its borderline it may be able to be used with Pela. See the CAR-T mouse data. 100% with Pela and Pela boost. This may accelerate the

[JohnnyYeg]

Oh, I think (nothing substantiative) there is PLENTY of interest with big pharma. I think ONCY is evaluating the best course of action for the company, to make best use of Pelareorep in the market place for cancer patients. The payout will be there, but I think there will be a more altruistic goal than just shareholder return. Remember, Matt Coffey started this journey after his mother was

[askretka]

Yes the guy who is in charge at the FDA who has final approvals on cancer drugs is tough on drug companies because his wife died of ovarian cancer. He knows very well what patients go through on the many toxic chemo drugs. His name is at the end of my last post. Richard Pazdur. --------------------------- For nearly two decades, Richard Pazdur has been the countrys key figure in approving new